I wouldn't say there was an issue, but there is a queue of approvals and, of course, drug manufacturers prefer the slow process to not change. You won't see the big names lobbying since they already do everything they can to minimize generics.
an NDA needs clinical trials, which we know several are already in phase 3.
I think stability testing can slow things down too, but there are enough big brains out there to figure out a safe way to accelerate that process. Perhaps even allow it to continue while the drugs are being used.
Let me be clear, that I am not part of the FDA nor do I work in regulatory capacity. But I've been around the manufacturing process for 2 decades, and attend all of that mandatory training and listen in to some of these types of meetings.
I think approvals take longer... we already had a lot of this worked out before the virus was discovered.